April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Monthly versus PRN Ranibizumab for Neovascular AMD: A Randomized Phase 2 Open-Label Study
Author Affiliations & Notes
  • Elijah Moon
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Mehran Taban
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Ben Sharareh
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Josh Wallsh
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Ron P. Gallemore
    Ophthalmology, Retina Macula Institute, Torrance, California
  • Footnotes
    Commercial Relationships  Elijah Moon, None; Mehran Taban, None; Ben Sharareh, None; Josh Wallsh, None; Ron P. Gallemore, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 133. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elijah Moon, Mehran Taban, Ben Sharareh, Josh Wallsh, Ron P. Gallemore; Monthly versus PRN Ranibizumab for Neovascular AMD: A Randomized Phase 2 Open-Label Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):133.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess efficacy of as needed (pro re nata, PRN) dosing of Ranibizumab versus monthly dosing of Ranibizumab for patients with wet age-related macular degeneration (AMD).

Methods: : A randomized, controlled clinical single-center trial comparing the efficacy of monthly versus PRN dosing of Ranibizumab (0.5 mg or 2.0 mg) for patients with wet AMD. High-resolution optical coherence tomography (HR-OCT) studies were used to guide PRN treatment and any cystic spaces or subretinal fluid prompted retreatment.

Results: : At 12 months, patients receiving PRN Ranibizumab had a mean increase in VA of 7.9 Early Treatment Diabetic Retinopathy Study (ETDRS) letters ± 1.1 standard error and a reduction of central macular thickness on HR-OCT of 58.3 microns ± 8.7 standard error (n = 40). Patients receiving monthly Ranibizumab had a mean increase in VA of 5.2 ETDRS letters ± 3.1 standard error and a reduction of central macular thickness on HR-OCT of 88.1 microns ± 19.4 standard error (n=30). Macular function assessed with multifocal ERG testing and microperimetry improved comparably in both the PRN and monthly groups.

Conclusions: : PRN dosing of Ranibizumab guided by HR-OCT appeared to maintain vision and improve macular function, but monthly dosing elicited a greater mean reduction in central macular thickness in wet AMD patients.

Clinical Trial: : http://www.clinicaltrials.gov NCT00764738

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×